Inhibrx (NASDAQ:INBX – Get Free Report) announced its earnings results on Monday. The company reported ($3.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.88) by ($0.21), Zacks reports. The company had revenue of $0.10 million for the quarter.
Inhibrx Stock Down 1.1 %
NASDAQ INBX opened at $13.94 on Tuesday. Inhibrx has a 52 week low of $10.80 and a 52 week high of $35.42. The stock’s 50-day moving average price is $13.33 and its 200-day moving average price is $14.67.
Analyst Ratings Changes
Separately, JMP Securities reiterated a “market perform” rating on shares of Inhibrx in a research note on Wednesday, January 22nd.
About Inhibrx
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
See Also
- Five stocks we like better than Inhibrx
- 3 Warren Buffett Stocks to Buy Now
- Kohl’s Posts Another Kitchen Sink Quarter, But New CEO Has a Plan
- High Flyers: 3 Natural Gas Stocks for March 2022
- Southwest Airlines Could Triple From Here—Here’s How
- 3 Dividend Kings To Consider
- Salesforce: An Early AI Opportunity With Long-Term Potential
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
